Vertex Inc. (VERX)
Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)
The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF franchise remains a dominant, reliable growth engine, with new revenue ramps from Casgevy and Journavx set to accelerate diversification. VRTX stock valuation is attractive: forward P/E is favorable versus peers, growth prospects are strong, and insider buying signals management confidence at current prices.
Here's What Key Metrics Tell Us About Vertex (VERX) Q2 Earnings
Although the revenue and EPS for Vertex (VERX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex (VERX) Q2 Earnings and Revenues Surpass Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago.
Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug
Shares of Vertex Pharmaceuticals (VRTX) sank 15% Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.
Vertex (VERX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Vertex (VERX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
Will Vertex (VERX) Beat Estimates Again in Its Next Earnings Report?
Vertex (VERX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex (VERX) Moves 5.0% Higher: Will This Strength Last?
Vertex (VERX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch
Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term data shows durable, life-changing benefits for SCD and TDT patients, but adoption is limited by a complex, intensive treatment process. Current Casgevy revenues are modest, but improvements to preconditioning and in-vivo approaches could unlock blockbuster potential by 2030.
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.
Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care. Eli Lilly's acquisition of SiteOne Therapeutics and STC-004 brings a once-daily NaV1.8 candidate, with early promising results but limited clinical data so far.
